S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Harrow, Inc. (NASDAQ:HROW), a pharmaceutical company with a market capitalization of $1.46 billion and impressive revenue growth of 48% over the last twelve months, announced Monday that its board of directors appointed Andrew R. Boll as president, effective immediately. According to InvestingPro data, the company maintains a strong gross profit margin of 75% despite current profitability challenges. Boll will continue to serve as the company’s chief financial officer and secretary, roles he has held since 2015 and 2012, respectively. The company stated that there were no changes to Boll’s compensation arrangement in connection with the appointment.
Also on August 21, the board appointed Randall E. Pollard as chief accounting officer, with his start date set for September 1, 2025. Pollard will oversee Harrow’s accounting operations, financial reporting, internal controls, and Securities and Exchange Commission reporting processes. He will report directly to Boll.
Pollard brings over 20 years of experience in public company financial reporting and corporate accounting leadership. He previously served as chief accounting officer of Cue Health, Inc. from April 2022 to June 2024 and held senior finance roles at Covis Pharmaceuticals, Inc. and Akorn. His appointment comes as Harrow shows strong momentum, with InvestingPro data revealing a 41% price return over the past six months, though the company currently operates with short-term obligations exceeding liquid assets. Pollard is a certified public accountant with a B.S. in Accounting from Pennsylvania State University and an MBA from Fairleigh Dickinson University.
According to the company’s statement, Pollard’s compensation includes an annual base salary of $400,000, a target cash bonus opportunity equal to 40% of his salary, and certain relocation expenses. He will also be eligible for six months of severance after completing 12 months of service. The company noted that there are no arrangements or understandings between Pollard and any other person regarding his appointment, and no related person transactions requiring disclosure.
Separately, the board approved and adopted amended and restated bylaws, effective August 21, 2025. The amendments designate the chief executive officer, rather than the president, as the principal executive officer of the company, clarify the respective roles of the chief executive officer, president, and chief financial officer, update officer titles and descriptions, and make technical and clerical edits.
This information is based on a press release statement filed with the Securities and Exchange Commission. InvestingPro analysis indicates that while Harrow maintains a "GOOD" overall Financial Health Score, analysts expect the company to return to profitability this year. For deeper insights into Harrow’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, along with 13 additional ProTips and extensive financial metrics.
In other recent news, Harrow Health has reported its second-quarter 2025 financial results, highlighting significant developments for investors. The company achieved a total revenue of $63.7 million, marking a 30% increase compared to the previous year. However, this figure fell short of some analysts’ expectations, with H.C. Wainwright projecting $68.0 million and another forecast at $66 million. Despite the revenue shortfall, Harrow Health exceeded earnings per share expectations, reporting $0.24 per share against the forecasted $0.01.
Additionally, Harrow Health’s net income for the quarter was $5.0 million, surpassing H.C. Wainwright’s estimate of $1.1 million. Analyst firms have responded positively to these results, with BTIG raising its price target for the company to $63.00, citing confidence in management’s 2025 sales guidance of $280 million. H.C. Wainwright also increased its price target to $64.00, maintaining a Buy rating on the stock. These developments reflect continued investor interest and optimism in Harrow Health’s strategic initiatives and product growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.